Why Is CHEMOURS CO (CC) Stock Down Today?

Why CC stock is down today

Chemours Co (CC) fell 18.63% to $14.59 on Wednesday, marking one of the largest single-day declines in its 52-week range of $10.44 to $28.67. The drop came after the company reported second-quarter results that failed to meet expectations despite in-line adjusted earnings per share. The stock's sharp decline reflects investor disappointment in the company's revenue performance and revised guidance.

What Happened

Chemours reported non-GAAP earnings per share of $0.42, which matched estimates. However, revenue of $1.59 billion fell short by $70 million, raising concerns about demand for its products. The company also cut its full-year sales guidance, narrowing the range from $5.982 billion to $6.098 billion to $5.866 billion to $6.098 billion. For the third quarter, Chemours expects sales between $1.511 billion and $1.591 billion, below the $1.601 billion estimate. The company cited weaker demand for its Opteon product line as a key factor behind the downward revisions.

The firm also announced a quarterly dividend of $0.0875 per share, payable on Sept. 15 to shareholders of record as of Aug. 14. While the dividend was in line with expectations, it did little to offset the broader concerns about the company's financial performance. An 8-K filing disclosed the results and financial details in conjunction with the earnings call.

What The Data Shows

Chemours has a market cap of $2.6 billion and is currently unprofitable, with a trailing twelve-month EPS of -2.73. The company's net margin is -7.0%, and its beta of 1.43 indicates higher volatility than the broader market. The stock is trading at a 2.05% dividend yield, but the recent earnings miss and guidance cut have likely eroded investor confidence. Intraday options data showed unusual activity, with $3.7 million in call premiums traded and a notable single print of $2.7 million. The stock has seen no significant retail chatter on social media in the past 24 hours.

What To Watch

Chemours has no scheduled earnings date in the immediate future. Investors will need to monitor coverage breadth and any further updates on demand trends in the Opteon business to gauge the stock's potential recovery.